Clinical ink’s Post

At Arctoris, we believe that, in drug discovery: Better Data → Better Decisions → Better Drugs ✨ How does your company deal with its data? How do you generate ML training datasets? What do you consider ML-compatible data? Let me know in the comments!

Neurodegeneration drug discovery has an attrition rate in the high 90% range and known issues with reproducibility. Variable protocols and non-physiologically relevant models all contribute to this, making data challenging to interpret in a wider context. AI/ML is only as good as the data being input, which is still the researcher's responsibility! Better Data > Better Decisions > Better Drugs

Unlocking the power of data in pathology with Matthew O. Leavitt, MD! 🎙️ Envision a future where data is not only affordable but also represents diverse patient populations. 📊 Dive into our chat about transforming data aggregation and setting new standards in pathology. 🚀 Link in the comments! 🎧 #PathNet #DigitalPathology #DataInnovation #HealthTech

How can you actually access the true potential of data in modern pathology? 🤔 In my recent conversation with Matthew O. Leavitt, MD, we explored the transformative power of efficient data aggregation. 🎙️ Matthew envisions a future where data is not only more affordable but also represents a broader cross-section of patient populations. It's like envisioning a library where every book is easily accessible, comprehensive, and in a standardized format. 📚 You can actually compare apples to apples that way. By leading pilot projects and aligning with pharmaceutical and life science companies, the goal is to set a new standard in data aggregation. Curious about this visionary approach to data in pathology? Dive into our in-depth discussion. Link in the first comment below. 🎧 #PathNet #DigitalPathology #DataAggregation #HealthTech #PathologyInnovation PathNet The DDx Foundation Lumea

🔔 Missed Alert! - See your missed notification from 7 days ago below 🔔 Last week we announced the launch of CGW Plus! That's right, this is an elevated, transformed, enhanced Clinical Genomics Workspace! Here's a sneak peek at some key features (we know you're curious!): 🔸 Expanded clinical and biological evidence review capabilities 🔸 Automated draft interpretive text for streamlined reporting 🔸 Comprehensive molecular results reporting 🔸 Adaptive learning and memory features 🔸 Dynamic PDF report rendering 🔸 Location-aware clinical trial matching interface At Velsera, we've reimagined CGW Plus to streamline your processes and ensure clinical laboratory professionals have instant access to the most accurate data. Discover how CGW Plus can revolutionize your clinical genomics workflow. Dive into the full press release for all the details! https://lnkd.in/gEhaa7rB #PrecisionMedicine #ClinicalGenomics #EraofVelsera #Pressrelease

💡 Get to know Bionano's new VIA™ software and get ready to visualize genomic data in ways you’ve never seen before. VIA offers intuitive visualization tools to help you gain greater insights from your #OGM, #NGS, and microarray data and to provide critical context for variant interpretation. Bionano recently featured Dr. Susan Crocker, director of cytogenetics at Kingston Health Sciences Centre, in a webinar where she shared insights into how the OGM workflow, including #VIA, is revolutionizing her research lab. 🖥️ Watch the webinar to learn more about how VIA can help you harness the full potential of your genomic data: https://bit.ly/3Rehg4S

Can financial engineering and data science cure cancer? Biomedical breakthroughs are occurring at an unprecedented pace. However, the binary risks of drug development make it challenging for institutional investors. Earlier today, Andrew Lo, Charles E. and Susan T. Harris Professor of Finance, Sloan School of Management, MIT, discussed how a portfolio approach, coupled with AI-based tools for measuring and managing risk, can improve risk-adjusted returns. #clc #dbpnif24

Today, on Clinical Trials Day, we recognize the invaluable contributions of diverse participants shaping the future of medicine. Understanding how individuals respond to treatments is pivotal, from genetic nuances to cultural intricacies. Discover how ProPharma's innovative RCO model offers tailored solutions to tackle barriers such as mistrust, access limitations, and cultural differences. Together, we can bridge gaps, address disparities, and pave the way for equitable healthcare. Download your copy of "Breaking Barriers: ProPharma's RCO Model and AI Solutions Propel Diversity in Clinical Trials for Inclusive Healthcare Innovation: https://lnkd.in/eP_YyeDS. Authors: Tiffany Rice, MSHS (she/her) and Kimberly Futch #ClincialTrialsDay #CTD2024

In clinical and research workflows, identifying artifacts is critical to ensuring the quality of downstream diagnostic procedures or image analysis. Register for our April 18 webinar to learn about the development of SlideQC BF 3.0, the latest version of our AI-based image quality control network, and discover how this tool can be used to detect and segment common artifacts, automatically triage slides, and improve workflow efficiency. Click to learn more! https://lnkd.in/gaTK47mN #digitalpathology #HALOimageanalysis #HALOai #HALOap #IndicaLabs

I hope you were able to tune in, but if not, check out the link below!